TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22528707
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (AADs) - responders
Study: 22528707
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (AADs) - long-term follow-up
Study: 20233135
Drug: Deferred invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred invasive treatment (balloon angioplasty or coronary bypass surgery)
Study: 20233135
Drug: Deferred invasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred invasive treatment
Study: 9797801
Drug: Sampatrilat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sampatrilat (50 mg, 100 mg, 200 mg)
Study: 2624612
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine (generic preparation P)
Study: 2624612
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nifedipine (reference preparation R)
Study: 30647445
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose guided by pharmacogenetics (LDG)
Study: 30647445
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose (MDG)
Study: 26098993
Drug: Baseline HCV
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline HCV RNA <400,000 IU/mL
Study: 16452738
Drug: Perioperative infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative infiltration mixture of local anesthetic and self-administered morphine
Study: 16452738
Drug: Self-administered morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered morphine only (Control)
Study: 11166665
Drug: Inactivated intra-nasal
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated intra-nasal anti-influenza vaccine
Study: 8938911
Drug: Low-dose antipsychotic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antipsychotic treatment
Study: 14511846
Drug: Lacidipine 2
Normalized name: lacidipine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 2 mg
Study: 30668281
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate 0.2 g/kg BM (SBC2)
Study: 30668281
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate 0.3 g/kg BM (SBC3)
Study: 29976736
Drug: Cumulative red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative red bone marrow dose from CT scans
Study: 26689864
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin (80 mg/m(2)) and paclitaxel (200 mg/m(2)) followed by concurrent chemoradiotherapy (66 Gy in 33 fractions, cisplatin 80 mg/m(2) days 1, 29 and 57, vinorelbine 15 mg/m(2) days 1, 8, 29, 36, 57 and 64)
Study: 26689864
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy followed by two cycles of cisplatin and paclitaxel
Study: 24769888
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of G-CSF-mobilized BMSCs
Study: 22318279
Drug: Ciprofloxacin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (250 mg orally twice daily for 3 days)
Study: 22318279
Drug: Cefpodoxime (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime (100 mg orally twice daily for 3 days)
Study: 2502734
Drug: Calcium mupirocin
Normalized name: Mupirocin Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium mupirocin 2% nasal ointment
Study: 30814387
Drug: Arthrocentesis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthrocentesis with lavage and hyaluronic acid injection (AS-group, n = 20)
Study: 26912531
Drug: Reading a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reading a metered dose inhaler (MDI) package insert pamphlet
Study: 26409153
Drug: Single-step time-lapse
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-step time-lapse medium (G-TL)
Study: 26409153
Drug: Sequential media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential media (G-1/G-2)
Study: 23069838
Drug: GLP-1 with
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 with insulin
Study: 15239094
Drug: peginterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alfa‐2b (1.5 microg/kg per week) and ribavirin (1000‐1200 mg/day) for 24 or 48 weeks depending on HCV genotype
Study: 11288040
Drug: Atorvastatin and
Normalized name: atorvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin and Bezafibrate
Study: 9303339
Drug: Pranlukast (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (225 mg b.i.d.) for 4 weeks
Study: 9303339
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (PSL, 5-15 mg/day)
Study: 29396374
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg twice daily for 24 months
Study: 27501597
Drug: Ramosetron 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramosetron 0.1 mg orally
Study: 27501597
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral corn starch)
Study: 23768747
Drug: Boceprevir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir (800 mg three times per day) plus peginterferon (1.5 μg/kg per week) and ribavirin (600-1400 mg per day) for 44 weeks
Study: 23768747
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus peginterferon (1.5 μg/kg per week) and ribavirin (600-1400 mg per day) for 44 weeks
Study: 23768747
Drug: Boceprevir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boceprevir (800 mg three times per day) plus peginterferon-ribavirin
Study: 20870230
Drug: Counseling through
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA spike protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling through oral presentations on menopause and HT (n=64)
Study: 18270769
Drug: Ropivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine infusion at the beginning of LC plus normal saline infusion at the end (Group B)
Study: 18270769
Drug: Ropivacaine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine infusion at the beginning of LC (Group A)
Study: 10423655
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg intravenous dolasetron
Study: 10423655
Drug: 1.8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg/kg intravenous dolasetron
Study: 1897345
Drug: Pancuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.01 mg.kg‐1 followed by suxamethonium 1.5 mg.kg‐1 in E1uE1a patients
Study: 1897345
Drug: Suxamethonium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1.5 mg.kg‐1 without pretreatment in E1uE1a patients
Study: 1897345
Drug: Pancuronium 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.01 mg.kg‐1 followed by suxamethonium 1.5 mg.kg‐1 in E1uE1u patients
Study: 1897345
Drug: Edrophonium injection
Normalized name: atropine / edrophonium Injection
DrugBank: Edrophonium (DB01010)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Edrophonium injection
Study: 6407503
Drug: Fluvoxamine (100-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (100-300 mg daily)
Study: 6407503
Drug: Chlorimipramine (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorimipramine (50-150 mg daily)
Study: 6407503
Drug: Fluvoxamine (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (150-300 mg three times daily)
Study: 6407503
Drug: Chlorimipramine (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorimipramine (150-300 mg three times daily)
Study: 29895378
Drug: Anti-rheumatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-rheumatic treatment (methotrexate monotherapy or anti-TNF therapy with or without methotrexate)
Study: 18533739
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with fibrinolytics and GP IIb/IIIa inhibitors
Study: 10720541
Drug: Live, attenuated,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live, attenuated, cold-adapted, trivalent influenza vaccine administered by nasal spray
Study: 8725709
Drug: Two-step warfarin
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step warfarin regimen beginning 10-14 days pre-operatively
Study: 8725709
Drug: Warfarin beginning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin beginning the night before surgery
Study: 1559048
Drug: Four-session social
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-session social learning based AIDS/drug injection prevention program
Study: 30796851
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) over 6 months
Study: 30796851
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) in before-and-after design
Study: 30607117
Drug: San Huang
Normalized name: Trimo San
DrugBank: Oxyquinoline (DB11145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: San Huang decoction (shd), taken twice daily for 1 day before surgery and for 7 days postoperatively.
Study: 30607117
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken twice daily for 1 day before surgery and for 7 days postoperatively.
Study: 24597798
Drug: n‐3 PUFAs
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFAs (3.4 g/day EPA and DHA ethyl‐esters)
Study: 22728519
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy (MPPT)
Study: 22728519
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy (MPPT) with alendronate
Study: 22728519
Drug: Methylprednisolone pulse
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone pulse therapy (MPPT) without alendronate
Study: 20669265
Drug: Once-daily extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily extended-release (ER) pramipexole
Study: 20669265
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) pramipexole
Study: 21704237
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (ER and IR)
Study: 17963457
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (2004-2005 or 2005-2006)
Study: 16255010
Drug: 7.5 mg/day
Normalized name: nicotine 7.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/day prednisolone
Study: 9354308
Drug: Sandimmune Neoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune Neoral and Neoplanta capsules, single dose of 175 mg
Study: 8442966
Drug: Prophylactic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic epidural saline (40 to 60 ml)
Study: 8442966
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood (15 ml) via epidural catheter
Study: 8442966
Drug: Fluids and
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluids and analgesics (control group)
Study: 28937147
Drug: Conbercept 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conbercept 0.5 mg
Study: 18499435
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of plain and hyperbaric bupivacaine (5mg each)
Study: 16599830
Drug: Mixed fruit
Normalized name: Goody's Mixed Fruit Blast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed fruit and vegetable juice powder concentrate, twice daily for 30 days
Study: 14535973
Drug: Antithyroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid therapy
Study: 11009241
Drug: Epinephrine infusion
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine infusion (40 microg/h) with bupivacaine 0.125% (8 mL/h)
Study: 9284763
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg p.o. 4 h before and 250 mg p.o. 1 h before GHRH
Study: 1607256
Drug: Ketanserin +
Normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin + Aspirin
Study: 3523718
Drug: Trimethoprim (TMP)
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim (TMP) and Sulfamethoxazole (SMZ) 160 mg/800 mg twice daily for five days
Study: 3523718
Drug: Trimethoprim (TMP)
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim (TMP) 200 mg twice daily for five days
Study: 3523718
Drug: Bicozamycin 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicozamycin 500 mg four times a day for three days
Study: 3523718
Drug: Furazolidone 100
Normalized name: furazolidone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone 100 mg four times a day for five days
Study: 22646240
Drug: Prasugrel (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (60 mg loading dose)
Study: 20836956
Drug: 1-visit indirect
Normalized name: DIRECT BLUE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-visit indirect pulp therapy (IPT)
Study: 20836956
Drug: 2-visit indirect
Normalized name: DIRECT BLUE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-visit indirect pulp therapy (IPT)
Study: 18671816
Drug: Everolimus 6
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 6 mg/day
Study: 18671816
Drug: Azathioprine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 2.5 mg/kg/day
Study: 3495505
Drug: No metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No metronidazole treatment (Control)
Study: 18495436
Drug: Ziprasidone IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone IM 20 mg
Study: 12944028
Drug: L-arginine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine with ISMN
Study: 1930351
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder (900 mg total dose)
Study: 6754508
Drug: Combined frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined frusemide (40 mg) and controlled-release potassium chloride (600 mg)
Study: 6754508
Drug: Frusemide and
Normalized name: furosemide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide and potassium supplements given as separate tablets
Study: 24611924
Drug: SAVR-S drug
Normalized name: Synovex S Drug Implant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAVR-S drug misuse subscale
Study: 15293649
Drug: Multi-couple group
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-couple group therapy
Study: 15293649
Drug: Individual couple
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual couple therapy
Study: 9697820
Drug: Fluvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (40 mg twice daily)
Study: 3486112
Drug: 150 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micrograms T4 + 150 micrograms KI daily
Study: 3486112
Drug: KI singly
Normalized name: KI
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KI singly or in combination
Study: 24765827
Drug: Antibiotic+steroid irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic+steroid irrigation of the middle ear
Study: 24765827
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of the same drops with systemic antibiotics
Study: 20430241
Drug: Telephone-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered cognitive behavioral therapy (T-CBT) for 12 weeks
Study: 15813663
Drug: Azithromycin 500mg
Normalized name: AZITHROMYCIN 500MG TAB
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500mg twice weekly for 6 months
Study: 9872190
Drug: Outpatient hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient hydration protocol (1,000 mL clear liquid over 10 h followed by 6 h of IV hydration at 300 mL/h)
Study: 9872190
Drug: Overnight IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight IV hydration (0.45 normal saline solution at 75 mL/h for 12 h precatheterization and postcatheterization)
Study: 16117981
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of infrared photocoagulation (IRP) and oral micronized purified flavonoid fraction (MPFF)
Study: 16117981
Drug: Oral micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral micronized purified flavonoid fraction (MPFF) alone
Study: 16117981
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of MPFF and IRP
Study: 12023410
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 or 10 mg per day)
Study: 8625179
Drug: Oral combination
Normalized name: clozapine ORAL COMBINATION PACKAGE (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral combination antiemetic regimen of metoclopramide (3 mg/kg x 2 then 2 mg/kg x 2 or 4 doses), dexamethasone (20 mg), and diphenhydramine (50 mg x 2 or 3 doses)
Study: 2185156
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course ceftriaxone (100 mg/kg on days one and two and 60 mg/kg thereafter for four, six, or seven days)
Study: 2185156
Drug: Full course
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full course therapy
Study: 6660438
Drug: Theo-Dur (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur (sustained-release preparation of theophylline), given twice daily
Study: 6660438
Drug: Nuelin (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuelin (conventional fast-release preparation), given three times daily
Study: 6660438
Drug: Theo-Dur (sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur (sustained-release preparation of theophylline)
Study: 6660438
Drug: Nuelin (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuelin (conventional fast-release preparation)
Study: 28508936
Drug: ZYAN1 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYAN1 10 mg
Study: 28508936
Drug: ZYAN1 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYAN1 300 mg
Study: 28508936
Drug: ZYAN1 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYAN1 single ascending doses (10, 25, 50, 100, 150, 200, 300 mg)
Study: 28508936
Drug: ZYAN1 multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYAN1 multiple doses (100, 150, 200, 300 mg every other day)
Study: 7710029
Drug: Extradural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural bupivacaine (either infusion of 0.125% or top‐ups of 10 ml of 0.25%)
Study: 7710029
Drug: Extradural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extradural bupivacaine with 2 micrograms.ml‐1 fentanyl
Study: 28816169
Drug: EBRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT with iridium implant (40 Gy/20 fractions + 35 Gy/48 hours)
Study: 28816169
Drug: EBRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBRT with iridium implant
Study: 17768282
Drug: Collaborative consultative
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Collaborative consultative service promoting the use of titration trials and periodic monitoring during medication maintenance.
Study: 8632218
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplement (210 mumol) + Albendazole (400 mg)
Study: 8632218
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) only
Study: 8632218
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplement (210 mumol) only
Study: 8632218
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplement + Albendazole (two groups)
Study: 8632218
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplement + Albendazole (third group)
Study: 1557640
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (folinic acid 200 mg/m2 + 5-FU 370 mg/m2 IV days 1 to 5 followed by weekly 5-FU 600 mg/m2, reduced to 500 mg/m2 due to toxicity)
Study: 1557640
Drug: Monotherapy (5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (5-FU 370 mg/m2 IV days 1 to 5 followed by weekly 5-FU 600 mg/m2)
Study: 1557640
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (initial dosage of 5-FU 600 mg/m2)
Study: 1557640
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (after reduction of 5-FU dosage to 500 mg/m2)